[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.127.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
October 16, 2013

FDA Tightens Indications for Using Long-Acting and Extended-Release Opioids to Treat Chronic Pain

JAMA. 2013;310(15):1547-1548. doi:10.1001/jama.2013.280076

In an effort to help curb the ongoing epidemic of prescription opioid abuse and overdoses, the US Food and Drug Administration (FDA) is tightening the indications for long-acting and extended-release versions of these drugs and is requiring the drugs’ manufacturers to conduct long-term postmarketing studies.

“The FDA is concerned about inappropriate use of [opioid pain medications], which has reached epidemic proportions in the United States,” said FDA Commissioner Margaret A. Hamburg, MD, during a press briefing in September.

First Page Preview View Large
First page PDF preview
First page PDF preview
×